Shares of Medgenics Inc (NASDAQ:GNMX) have earned a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation. Medgenics’ rating score has declined by 20% from 90 days ago as a result of various analysts’ upgrades and downgrades.
Analysts have set a twelve-month consensus price target of $5.00 for the company and are expecting that the company will post ($0.15) EPS for the current quarter, according to Zacks. Zacks has also assigned Medgenics an industry rank of 241 out of 265 based on the ratings given to its competitors.
An institutional investor recently raised its position in Medgenics stock. Wells Fargo & Company MN boosted its holdings in shares of Medgenics Inc (NASDAQ:GNMX) by 433.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 130,662 shares of the biotechnology company’s stock after buying an additional 106,178 shares during the quarter. Wells Fargo & Company MN owned 0.35% of Medgenics worth $165,000 at the end of the most recent reporting period. 20.44% of the stock is owned by institutional investors and hedge funds.
Shares of GNMX remained flat at $$1.83 during trading hours on Monday. 98,611 shares of the stock were exchanged, compared to its average volume of 103,685. The company has a market cap of $108.59, a price-to-earnings ratio of -2.20 and a beta of 1.03. Medgenics has a 52-week low of $0.98 and a 52-week high of $2.65.
Medgenics (NASDAQ:GNMX) last posted its quarterly earnings data on Tuesday, March 13th. The biotechnology company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. analysts expect that Medgenics will post -0.63 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Medgenics Inc (GNMX) Given Consensus Recommendation of “Hold” by Brokerages” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/medgenics-inc-gnmx-given-consensus-recommendation-of-hold-by-brokerages.html.
Medgenics Company Profile
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn's disease.
Get a free copy of the Zacks research report on Medgenics (GNMX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with MarketBeat.com's FREE daily email newsletter.